Instem plc announced that it has appointed Mary Dolson as an Independent Non-Executive Director to the Board and Chair of the Audit Committee, effective 9 January 2023. Mary will also join the Remuneration and Nomination Committees immediately upon appointment. Mary is an expert advisor on regulatory, financial and accounting compliance issues, with extensive experience advising businesses in the pharmaceutical, biotech and life science sectors.

She is a specialist and experienced advisor in taking companies through periods of change, from start-up to venture capital investments to public offerings. Most recently, Mary was a Non-Executive Director at Nuvelution Pharma Inc. (Boston, USA) between 2019 and 2021, where she consulted as an expert in finance, modelling, and risk across all phases of the pharmaceutical and biotech industry. Mary has spent most of her career in audit and served as a PwC partner in London for over 20 years, where she became the Global Lead on pharmaceutical industry accounting and reporting before retiring in 2018.

Mary was a founding member of the 'Pharma Forum', an industry based International Financial Reporting Standards working group. Mary served as a Non-Executive Committee Member for the Financial Reporting Review Panel (UK), a position she held from 2011 until 31 December 2020 (when it was dissolved). In this role, Mary helped to guide the implementation of accounting standards, corporate governance, and other reporting codes.

Mary is a Bachelor of Business Accounting graduate of Pace University, Lubin School of Business, New York, and a Certified Public Accountant (CPA) in the State of New York. Revised Board and Committee Membership. Effective with Mary's appointment, Board committee membership has been revised as follows: Audit Committee consists: Mary Dolson - chair, Riaz Bandali, Mike Mcgoun.

Remuneration Committee consists: Riaz Bandali - Chair, Mary Dolson and Mike McGoun. Nomination Committee consists David Gare - Chair, Mary Dolson, Riaz Bandali and Mike McGoun. Committee membership will be reviewed periodically in line with good governance practice.

Following completion of Mary's initial on-boarding process, David Sherwin (Non-executive Director) has indicated that he intends to retire from the Board, with a confirmatory announcement to be made at that time. The Company is also announced that John Alarcon has been appointed into a full-time employee position as Vice President of Strategic Partnerships and Vice President of US Finance. John joined Instem on a contract basis in 2019 and led the buy-side due diligence, modelling, and integration efforts on the d-Wise acquisition, and supported on those of The Edge and PDS Life Sciences.

More recently he took responsibility as Interim Controller for Instem's Clinical Trial Acceleration business unit. John draws on over a decade's finance experience with VC backed technology companies and prior to joining Instem was running his own consulting practice. In his new role based in the US, John will head Instem's US Finance team and will report to Chief Financial Officer, Nigel Goldsmith.